The Biggest Problem With Moderna Has Nothing to Do With Its Recent Earnings Miss
Shares of COVID-19 vaccine-maker Moderna (NASDAQ: MRNA) have been falling quickly in recent months. In the past three months, the stock has declined 40%, while the S&P 500 has risen by 5%. To make matters worse, the company is coming off a disappointing earnings performance that could send its shares even lower.
But the disappointing results should be the least of investors' worries. There could be much greater challenges ahead for Moderna.
Image source: Getty Images.
Source Fool.com
